Abstract
A strong association between dystonia and tremor has been known for more than a century. Two forms of tremor in dystonia are currently recognized: 1) dystonic tremor, which is tremor produced by dystonic muscle contraction and 2) tremor associated with dystonia, which is tremor in a body part that is not dystonic, but there is dystonia elsewhere. Both forms of tremor in dystonia frequently resemble essential tremor or another pure tremor syndrome (e.g., isolated head and voice tremors and task-specific writing tremor), and relationships among these tremor disorders have long been debated. Misdiagnosis is common because mild dystonia is frequently overlooked in patients with tremor. It is now clear that essential tremor is a syndrome, not a specific disease, and the use of essential tremor as a specific clinical diagnosis is arguably an impediment to elucidating this and other pure tremor syndromes and their relationship to dystonia. A new classification, primary tremor, is proposed and would be used for any disorder in which tremor is the sole or principal abnormality with no identifiable etiology other than possible genetic inheritance. This classification scheme would facilitate tremor research by moving the focus from the narrow question “Is it essential tremor?” to a broader consideration of what genetic and environmental factors cause primary tremor disorders, and how do they relate to dystonia and other neurological disorders.
Keywords: Dystonia, essential tremor, tremor
Current Neuropharmacology
Title:Defining Dystonic Tremor
Volume: 11 Issue: 1
Author(s): Rodger J. Elble
Affiliation:
Keywords: Dystonia, essential tremor, tremor
Abstract: A strong association between dystonia and tremor has been known for more than a century. Two forms of tremor in dystonia are currently recognized: 1) dystonic tremor, which is tremor produced by dystonic muscle contraction and 2) tremor associated with dystonia, which is tremor in a body part that is not dystonic, but there is dystonia elsewhere. Both forms of tremor in dystonia frequently resemble essential tremor or another pure tremor syndrome (e.g., isolated head and voice tremors and task-specific writing tremor), and relationships among these tremor disorders have long been debated. Misdiagnosis is common because mild dystonia is frequently overlooked in patients with tremor. It is now clear that essential tremor is a syndrome, not a specific disease, and the use of essential tremor as a specific clinical diagnosis is arguably an impediment to elucidating this and other pure tremor syndromes and their relationship to dystonia. A new classification, primary tremor, is proposed and would be used for any disorder in which tremor is the sole or principal abnormality with no identifiable etiology other than possible genetic inheritance. This classification scheme would facilitate tremor research by moving the focus from the narrow question “Is it essential tremor?” to a broader consideration of what genetic and environmental factors cause primary tremor disorders, and how do they relate to dystonia and other neurological disorders.
Export Options
About this article
Cite this article as:
J. Elble Rodger, Defining Dystonic Tremor, Current Neuropharmacology 2013; 11 (1) . https://dx.doi.org/10.2174/1570159X11311010007
DOI https://dx.doi.org/10.2174/1570159X11311010007 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Role of Azoles in Cancer Prevention and Treatment: Present and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry 5-HT7 Receptor Ligands: Recent Developments and Potential Therapeutic Applications
Mini-Reviews in Medicinal Chemistry Eurycoma longifolia, A Potential Phytomedicine for the Treatment of Cancer: Evidence of p53-mediated Apoptosis in Cancerous Cells
Current Drug Targets Preface
Central Nervous System Agents in Medicinal Chemistry Determination of Phytochemicals by GC-MS in Two Fractions (17 and 21) of Methanol Extract of Loranthus Micranthus and their Antioxidant and Anti-Inflammatory Activity
The Natural Products Journal The Fate of Nanocarriers As Nanomedicines In Vivo: Important Considerations and Biological Barriers to Overcome
Current Medicinal Chemistry Recent Advances in Potential Therapeutic Drugs for Cognitive Impairment in Schizophrenia
Current Psychiatry Reviews Wnt Signaling in Rhabdomyosarcoma – A Potential Targeted Therapy Option
Current Drug Targets Nano - Based Therapeutic Strategies in Management of Rheumatoid Arthritis
Recent Patents on Nanotechnology Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry The Universal Nature, Unequal Distribution and Antioxidant Functions of Melatonin and Its Derivatives
Mini-Reviews in Medicinal Chemistry Recent Advances in Immunotherapy for Allergic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synaptic Activity-Regulated Wnt Signaling in Synaptic Plasticity, Glial Function and Chronic Pain
CNS & Neurological Disorders - Drug Targets Recent Advances in Physical Approaches for Transdermal Penetration Enhancement
Current Drug Therapy Signal Pathways Mediating Antidepressant and Antipsychotic Drugs on Neuronal Cell Survival
Current Medicinal Chemistry - Central Nervous System Agents Autoantibodies and Sjogren’s Syndrome: A Physiologist’s Perspective
Current Pharmaceutical Biotechnology The Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option
Current Neuropharmacology Association between the Regulator of G-protein Signaling 9 Gene and Patients with Methamphetamine Use Disorder and Schizophrenia
Current Neuropharmacology Current Management of Obstetric Fistula: Implication for the Low Resource Areas
Current Women`s Health Reviews